JNJ

Johnson JohnsonC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$290.00

+14.6% vs current

Most likely

Base case

55%

Probability

Target price

$271.43

+7.3% vs current

B-

Bear case

20%

Probability

Target price

$225.00

-11.1% vs current

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

The earnings release is fundamentally positive, but the latest price snapshot shows a roughly 2.7% decline, producing mixed near-term sentiment. News attention is high; social, options, short-interest, employee, and fresh analyst-revision evidence are unavailable. The appropriate stance remains constructive but monitoring-oriented.

RankAlpha Sentiment Codex - 2026-07-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-16catalystQ2 results and raised outlook support the earnings floorMedium impact

Q2 reported sales grew 6.6% to $25.3 billion, adjusted EPS rose 4.7% to $2.90, and management raised 2026 reported-sales and adjusted-EPS guidance. The positive fundamental signal is tempered by an approximately 2.7% price decline in the latest market snapshot. [#SEC-8K-2026-07-15]

2026-12-08eventEnterprise Business Review provides a dated strategic checkpointMedium impact

The December 8, 2026 Enterprise Business Review is the clearest scheduled opportunity for management to update investors on growth, portfolio priorities, separation execution, and capital allocation. [#SEC-8K-2026-04-14]

2026-12-31catalystNew-product growth must offset STELARA pressureMedium impact

Innovative Medicine growth was driven by DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, TREMFYA, SPRAVATO, and CAPLYTA, but STELARA reduced segment growth by approximately 760 basis points. Continued launch, regulatory, and pipeline execution is therefore the key medium-term test. [#SEC-8K-2026-07-15]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology